Has Amanda Fontenot, MD received payments from drug or device companies?

Yes. Drug and device makers reported $142,470 in general payments to Amanda Fontenot, MD across 186 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Amanda Fontenot, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Amanda Fontenot, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Amanda Fontenot, MD

Internal Medicine · Marrero, LANPI 1356531131

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $122,007 of the $142,470 with a category attached, or 85.6%. 3 manufacturers reported payments, led by Lilly USA, LLC at 52.2% of the total. Among internal medicine clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$142,470in general payments, 2019–2025

Across 186 payments — averaging $765.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lilly USA, LLC$74K
Novo Nordisk$68K
Boehringer Ingelheim$122

What the payments were for

Speaking & faculty fees$122,00786%
Travel & lodging$14,67610%
Food & beverage$5,6594%
Education$1290%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lilly USA, LLC	112	$74,393
Novo Nordisk	73	$67,955
Boehringer Ingelheim	1	$122

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ZEPBOUND$67,035
Wegovy$46,536
Saxenda$20,421

How this compares

$142,470 in reported general payments places this provider in the 95th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana →

Medicare billing

Part B allowed, 2024

$16,428

Medicare patients

Services billed

208

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OzempicSemaglutide	394	$653,239
MounjaroTirzepatide	428	$526,805
WegovySemaglutide	273	$372,069
TrulicityDulaglutide	15	$21,532
Topiramate	587	$7,151
Naltrexone Hcl	26	$2,753
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	12	$418
Metformin Hcl ErMetformin Hcl	72	$381
Bupropion XlBupropion Hcl	14	$339
Pantoprazole Sodium	11	$200
Metformin Hcl	14	$47
Lorazepam	12	$23

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Novo NordiskOzempic, Wegovy	$67,955	$1,025,308667 claims
Lilly USA, LLCMounjaro, Trulicity	$74,393	$548,336443 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Marrero

Alan BowersMarrero$20K
Hong NguyenMarrero$15K
Shibu VarugheseMarrero$13K
Donna RyanBaton Rouge$991K
Steven DeitelzweigNew Orleans$939K
Bruce SamuelsCovington$200K
John SchwabBaton Rouge$122K
Daniel EnglertNew Orleans$74K
Everett BrownGretna$71K
Rajan KhannaShreveport$54K

See the full list for Louisiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →